Konferenzpaper

Jahr der Veröffentlichung: 2009

Seiten: S108-S117

Zeitschrift: Journal of the American College of Cardiology

Bandnummer: 54

Heftnummer: 1

ISSN: 0735-1097

Open Access Status: Green

DOI Link: https://doi.org/10.1016/j.jacc.2009.04.014

Konferenz: 4th World Symposium on Pulmonary Hypertension

Verlag: Elsevier

Abstract: 
Over the past 2 decades, pulmonary arterial hypertension has evolved from a uniformly fatal condition to a chronic, manageable disease in many cases, the result of unparalleled development of new therapies and advances in early diagnosis. However, none of the currently available therapies is curative, so the search for new treatment strategies continues. With a deeper understanding of the genetics and the molecular mechanisms of pulmonary vascular disorders, we are now at the threshold of entering a new therapeutic era. Our working group addressed what can be expected in the near future. The topics span the understanding of genetic variations, novel antiproliferative treatments, the role of stem cells, the right ventricle as a therapeutic target, and strategies and challenges for the translation of novel experimental findings into clinical practice. (J Am Coll Cardiol 2009;54:S108-17) (C) 2009 by the American College of Cardiology Foundation

Harvard-Zitierstil: Ghofrani, H., Barst, R., Benza, R., Champion, H., Fagan, K., Grimminger, F., et al. (2009) Future Perspectives for the Treatment of Pulmonary Arterial Hypertension, Journal of the American College of Cardiology, 54(1), pp. S108-S117. https://doi.org/10.1016/j.jacc.2009.04.014

APA-Zitierstil: Ghofrani, H., Barst, R., Benza, R., Champion, H., Fagan, K., Grimminger, F., Humbert, M., Simonneau, G., Stewart, D., Ventura, C., & Rubin, L. (2009). Future Perspectives for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology. 54(1), S108-S117. https://doi.org/10.1016/j.jacc.2009.04.014